ClinicalTrials.gg
Sign In

Anemia, Hemolytic, Autoimmune clinical trials

The registry lists 103 studies for Anemia, Hemolytic, Autoimmune across more than 10 countries. 39 are recruiting or about to start. 79 of them are mainly about Anemia, Hemolytic, Autoimmune (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Anemia, Hemolytic, Autoimmune studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
31
Recruiting
24
Not yet recruiting
14
Active, not recruiting
11
Terminated
9
Status unknown
8

Phase

Phase 2
36
Phase 1
25
Phase 3
16
Early Phase 1
9
Phase 4
1

Where

China
39
United States
31
Italy
22
Germany
18
France
18
United Kingdom
18

Who runs them

Institute of Hematology & Blood Diseases Hospital, China (15) · University Hospital, Bordeaux (5) · Assiut University (5) · Bioverativ, a Sanofi company (5) · Sanofi (4) · Peking Union Medical College Hospital (4) · Rigel Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (3)

What is being tested here

Drugs under test in Anemia, Hemolytic, Autoimmune studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
YTS109204
Ibrutinib102
Iptacopan102
Zolacabtagene autoleucel101
Inaticabtagene autoleucel101
Rilzabrutinib111
GT801101
CM336101
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312101
Zanubrutinib101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open

Coming up

7phase 3 studies under way
17studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger. 5 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
105 (21%)5 (21%)
1823 (96%)23 (96%)
3023 (96%)23 (96%)
4023 (96%)23 (96%)
5023 (96%)23 (96%)
6522 (92%)22 (92%)
7519 (79%)19 (79%)
8514 (58%)14 (58%)

Across all 103 studies, recruiting or not: 26% stop at 75 or younger and 12% at 65; 22% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Stopped2

Studies

Recruiting first, then most recently updated. Showing 50 of 103. Browse all 103 → or search them.